At the 14th International Congress on Myeloproliferative Neoplasms, research into the case of dizygotic twins with essential thrombocythemia won the Best overall Abstract Award for concluding how their rare stem cell disorder was passed between both twins.
At the 14th International Congress on Myeloproliferative Neoplasms, Srdan Verstovsek, MD, PhD, reviewed the research supporting the optimal use of JAK inhibitors in patients with myelofibrosis.
Following JAK inhibitor therapy, multiple agents are showing the ability to reduce symptoms and spleen volume while improving survival in patient with myelofibrosis.
During a presentation at the 14th Annual International Congress on Myeloproliferative Neoplasms, Naveen Pemmaraju, MD, discussed the current agents being examined for MPNs.